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Abstract: The glycogen storage disease (GSD) is a group of inherited disorders that involve deficiencies in the enzymes 
that metabolize glycogen. The purpose of the present paper is to report a rare case of GSD type 1b that presented both pe-
ripheral and central giant cell granuloma, and to discuss the possible explanation for this unusual finding. The use of cor-
ticosteroids in the management of central giant cell granuloma is also demonstrated. 
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INTRODUCTION 
Specific enzymes breakdown molecules of glycogen into 
glucose, which is used as a source of energy by the organ-
ism. The glycogen storage disease (GSD) is a group of inher-
ited disorders that involves deficiencies in such enzymes [1]. 
The GSD is a rare autosomal recessive disease, and it exists 
in a variety of forms in accordance to specific enzymes in-
volved [2]. 
In the GSD type1b, the enzyme glucose-6-phosphatase 
(G6P) cannot be transported across the microsomal mem-
brane in the liver, and the glycogen cannot be metabolized 
[3]. The glycogen accumulates in several organs, such as 
liver and kidneys [4, 5], and the disease leads to systemic 
and intraoral manifestations. The main systemic manifesta-
tions are hypoglycemia, hyperlipidemia, hyperuricemia, he-
patomegaly, short stature, growth retardation, neutropenia, 
and neutrophilic dysfunction with recurrent infections [6, 7]. 
Patients with GSD1b show poor prognosis and high mortal-
ity rate [8]. 
The oral manifestations of GSD1b include severe perio-
dontitis, bleeding diathesis, oral ulcerations, and dental car-
ies [9, 10]. A rare case of peripheral giant cell lesion associ-
ated with this disease has been previously described [11]. 
The purpose of the present paper is to report a GSD1b pa-
tient who presented both peripheral and central giant cell 
granuloma, and discuss a possible explanation for this un-
usual finding. The use of corticosteroids in the management 
of this condition is also demonstrated. 
CASE REPORT  
A male patient with consanguineous parents was first di-
agnosed with GSD type 1b when he was six months old. At 
age 24, the Hematology Center referred him to the Oral Di-
agnosis Service of the Federal University of Minas Gerais to 
treat a hyperplasic lesion in the oral mucosa. 
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As a consequence of lipid disturbance, the patient had his 
gallbladder removed. He presented hepatomegaly, hypogly-
cemia, short stature, and many previous episodes of recurrent 
infections including hospitalizations due to the neutropenia. 
In his first appointment, he showed low neutrophil numbers 
(1.05 x10
9 /L; normal range from 1.7 to 8.0 x10
9 /L) and a 
high level of uric acid (11 mg/dl; normal range from 3.4 to 
7.0 mg/dl). He was being treated with Granulokine 30 
(Roche, Switzerland) for about 10 years (subcutaneous injec-
tion/ 1ml / alternating days), which is a granulocyte colony-
stimulating factor (G-CSF) and with Allopurinol (Glaxos-
mithKline, Rio de Janeiro, Brazil) (100 mg / 2x day) for uric 
acid control. Besides these drugs, he was also taking a vita-
min complex (Protovit Plus) (Bayer, Rio de Janeiro, Brazil).  
Intraoral assessment showed high levels of plaque and 
calculus, severe periodontitis with edematous gingiva, ab-
sence of tooth # 47, dental caries and a hyperplasic purplish 
lesion in the lingual aspect localized adjacent to the teeth 32, 
33 and 34 (Fig. 1A). There was also a purplish tumoral le-
sion in the posterior alveolar ridge between teeth # 46 and 48 
(Fig. 1B). The panoramic x-ray image of this area (Fig. 2A 
and 2B) revealed a nonspecific ill-defined rarefaction, with-
out evidence of sclerosis at the margins. Widening of the 
periodontal ligament space, lamina dura destruction, and 
narrowed roots were present in those teeth. The axial com-
puted tomography (CT) image (Fig. 2C) demonstrated that 
such lesion was non-expansible and extended to the man-
dibular canal. In addition, the lingual cortical and the alveo-
lar bone were destroyed as confirmed by the coronal CT. 
The patient underwent comprehensive non-surgical 
periodontal therapy. Teeth 26, 28, 36, 37, 46 and 48 were 
removed due to advanced periodontal disease. Based on a 
provisional diagnosis of pyogenic granuloma or peripheral 
giant cell granuloma, the anterior hyperplasic lesion was 
entirely removed through excisional biopsy. Histological 
examination confirmed the diagnosis of peripheral giant cell 
granuloma (Fig. 3A and 3B). In the posterior intra-osseous 
lesion, a fine needle aspiration biopsy was performed, but it 
was not contributive. Thus, an incisional biopsy was done 
and the time teeth 46 and 48 were extracted. The histological Oral Giant Cell Granuloma in a Patient with Glycogen  The Open Dentistry Journal, 2009, Volume 3    145 
diagnosis was central giant cell granuloma (Fig. 3C and 3D). 
The parathyroid hormone level was within the normal limits. 
After a discussion with the medical staff on how to approach 
the case, the intraosseous lesion was conservatively treated. 
A total volume of 0,5 ml
 injections of corticosteroid (triam-
cinolone, 20 mg/ml) and local anaesthetic solution (lidocaine 
2%, 1:1) [12, 13] were used. Intralesion applications were 
performed every fifteen days for three times. Two weeks 
after the third application, clinical and radiographic examina-
tions suggested regression of the lesion and no further appli-
cations were necessary. There was no evidence of recurrence 
after 1 year of follow-up. 
DISCUSSION 
This case report emphasizes the importance of a 
multidisciplinary approach in the treatment of a patient with 
GSD type 1b. G-CSF and granulocyte-macrophage colony-
stimulating factor (GM-CSF) are usually used to increase 
granulocytes levels, and were described as being successful 
in reducing the number of recurrent infections associated 
with GSD type 1b [14]. In the current report, the patient had 
been using G-CSF for 10 years, and presented central and 
peripheral giant cell granulomas. 
Although speculative, we found a possible explanation 
between the use of G-CSF / GM-CSF and the development 
of giant cell granulomas. Both G-CSF and GM-CSF act in 
extracellular membrane receptors, such as c-fms. These re-
ceptors activate an important signaling pathway that differ-
entiates progenitor myeloid cells into osteoclasts [15]. The 
multinucleated giant cells found in central and peripheral 
giant cell lesions present ultrastructural characteristics of 
osteoclasts [16]. Therefore, theoretically, the giant cell le-
sions reported in the present paper may have developed due 
to the constant stimulation of osteoclastogenesis induced by 
the G-CSF. It is important to note that the other case report 
of peripheral giant cell granuloma associated with GSD 1b 
found in the literature was also in a patient who was using G-
CSF [11]. 
Despite this possible side-effect, such patients cannot in-
terrupt the G-CFS usage due to the neutropenic state. The 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Clinical aspects of the peripheral (A) and central giant cell 
lesion (B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Radiographic aspects of the central giant cell lesion. Panoramic x-ray depicting the lesion in the mandible (A and B). Axial CT 
showing bone destruction of the rigth side of the mandible measuring 13x5mm (C). Panoramic x-ray after 1 year of follow-up (D). 146    The Open Dentistry Journal, 2009, Volume 3  Amaral et al. 
patient of the current report is under follow-up for early di-
agnosis of possible additional lesions. It is important to men-
tion that patients with GSD may be more susceptible to in-
flammatory periodontal disease. For that reason, such pa-
tients should be under strict maintenance protocols to control 
their periodontal health. 
Corticosteroids usage has been previously reported in the 
management of central giant cell lesions [12, 13]. This same 
approach in a patient with GSD was successfully described 
for the first time in this paper.  
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Fig. (3). Histopathological features of the peripheral (A and B) (Original magnification x 100 and x 400, respectively) and central giant cell 
lesions (C and D) (Original magnification x 100 and x 400, respectively). 